Publication date: Jun 06, 2026
The COVID-19 pandemic disrupted healthcare systems and may have influenced mortality trends in hematologic-immune disorders (D50-D89) and Diseases of the circulatory system (I00-I99). This study evaluates US mortality trends from 2010 to 2023 to assess potential pandemic-related changes. We utilized spline regression modeling on CDC WONDER mortality data (2010-2023) to quantify post-pandemic trend shifts in both age-adjusted and sex/age-stratified mortality rates. Post-2019 mortality trends for D50-D89 and I00-I99 diseases showed significant increases, particularly among older adults and younger males. D50-D89 mortality in females ≥ 65 increased ~ 2. 6% (95% CI 1. 70% to 3. 68%) annually, while males ≥ 65 increased ~ 1. 6% (95% CI 0. 28% to 3. 07%) annually; younger males (15-34 years) showed a 4. 5% (95% CI 0. 49% to 8. 87%) annual increase. I00-I99 mortality increases were most pronounced in older females (~ 1. 4% annual increase, 95% CI 0. 49 to 2. 31). Analysis of standardized rates in all groups except for men in I00-I99 showed a positive slope-shift after 2019. (p
Open Access PDF
| Concepts | Keywords |
|---|---|
| Females65 | Blood disorders |
| Hematologic | Circulatory System disorders |
| Pandemic | COVID-19 pandemic |
| Hematologic disorders |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Covid-19 pandemic |
| disease | MESH | immune disorders |
| pathway | REACTOME | Reproduction |
| disease | MESH | included |
| drug | DRUGBANK | Tilmicosin |
| drug | DRUGBANK | Coenzyme M |